Karl Pfleger urged Bryan Johnson to invest in aging research and companies

Karl Pfleger urged Bryan Johnson to invest in aging research and companies

Investor and AgingBiotech.info founder Karl Pfleger urged Bryan Johnson to direct a meaningful share of his money and public influence toward aging research. His argument concerns how Johnson spends his next dollar: personal measures can help him survive until future therapies arrive, while funding for laboratories, biotechnology companies, and clinical trial reform could bring those therapies closer.

On July 17, Karl Pfleger wrote that Johnson has his priorities wrong. Pfleger's reasoning is that a 49-year-old person may have several decades of life ahead, so interventions developed by geroscience during that time are likely to have a greater effect on his fate.

“What the aging field can produce over the next three to four decades will matter more to his life than anything available today,” Pfleger writes.

A personal protocol addresses one question: how to reduce the risk of dying now. Sleep, nutrition, exercise, treatment for disease, and available medical care can give a person more time. Johnson is already turning this approach into a service. In June, he launched Immortals Medicine, where doctors remotely prescribe medications from his protocol.

Pfleger asks a different question: what should a wealthy supporter do after securing this additional time? He proposes funding nonprofit research, investing in companies that turn biological ideas into medicines, and advocating for rules that allow faster testing of therapies for age-related diseases. Geroscience studies the mechanisms of aging. Without funding for experiments, trials, and manufacturing, its discoveries will remain confined to papers and mouse models.

There is a mechanism behind this position. Personal spending changes the health of one person through measures that are already available. A donation to a laboratory, an investment in a biotechnology company, or a political campaign can fund experiments, teams, and clinical trials. A successful therapy could then help many people, including the person who helped make it possible.

Pfleger argues that this is where a wealthy immortalist can achieve the greatest return on the next dollar: by supporting future methods that address the causes of aging. He also writes that he has personally invested in more than 30 rejuvenation companies. This is his own statement.

Pfleger does not provide a public breakdown of Johnson's spending or calculate how much each of his proposals would accelerate the development of a therapy. The disagreement therefore remains one of priorities. He proposes that a wealthy immortalist judge the next dollar by how much research, how many companies, and how many trials it can set in motion.